Jun 2 2015
BioStructures, LLC, a privately held orthobiologics company, announced today the first application of Prohesion™, its new surgical wound technology.
Prohesion™ is an activated type I collagen wound filler indicated for the management of surgical wounds. The patented technology utilizes type I collagen fragments that have been sheared to an optimal size, producing a form that requires less time for the body to break down and can jump start collagen's role in wound management. The powder format allows complete and liberal coverage of surgical wounds. Prohesion Hydrolyzed Surgical Powder is effective in all phases of wound care, including inflammation, proliferation, granulation, remodeling and maturation, as well as in infected wounds.
Russell Cook, CEO of BioStructures stated, "We are very pleased to offer another unique and innovative product under the BioStructures umbrella. Utilizing our expertise in collagen, we are able to offer products that not only assist in better patient care but will benefit the hospital by reducing complications with surgical wounds. Prohesion™ provides yet another technology platform expanding on our Bioactive, Collagen, Synthetic, DBM and Allograft suite of products."
Squid-inspired technology could replace needles for medications and vaccines